Treatment of Hepatocellular Carcinoma with Portal Vein Thrombosis by Sorafenib Combined with Hepatic Arterial Infusion Chemotherapy.
- Author:
Mi Yean YANG
1
;
Soung Won JEONG
;
Dong Kyun KIM
;
Sang Gyune KIM
;
Jae Young JANG
;
Young Seok KIM
;
Joon Seong LEE
;
Boo Sung KIM
;
Jung Hoon KIM
;
Yong Jae KIM
Author Information
1. Institute for Digestive Research, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea. jeongsw@hosp.sch.ac.kr
- Publication Type:Case Report
- Keywords:
Hepatocellular carcinoma;
Portal vein thrombosis;
Sorafenib;
Hepatic arterial infusion chemotherapy
- MeSH:
Carcinoma, Hepatocellular;
Cisplatin;
Fluorouracil;
Humans;
Middle Aged;
Niacinamide;
Phenylurea Compounds;
Portal Vein;
Prescriptions;
Thrombosis
- From:Gut and Liver
2010;4(3):423-427
- CountryRepublic of Korea
- Language:English
-
Abstract:
Treatment with sorafenib prolongs both the median survival and time to progression by nearly 3 months in patients with advanced hepatocellular carcinoma. Although the effects of combining sorafenib therapy with other anticancer treatment modalities have not been clarified, combination treatment is strongly expected to be beneficial. We report the case of a 50-year-old man who exhibited a partial response and portal vein thrombosis (PVT) revascularization after sorafenib combined with hepatic arterial infusion chemotherapy (HAIC). He exhibited a decrease in tumor size and PVT after 2 months of sorafenib monotherapy. However, no additional response was seen during the subsequent 2 months. To achieve a better tumor response, we combined HAIC with sorafenib. Daily cisplatin (7 mg/m2 on days 1-5) and 5-fluorouracil (170 mg/m2 on days 1-5) were infused repeatedly every 4 weeks, and the sorafenib prescription was modified. After four cycles of combined therapy, both the tumor size and PVT were much improved and exhibited partial response.
